US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

39.37

-0.0843-0.21%

Volume:6K

Turnover:250.29K

Market Cap:7.87M

PE:- -

High:39.87

Open:39.87

Low:39.22

Close:39.46

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.82

T/O Rate:3.17%

Dividend:0.32

Dividend Rate:0.81%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156

THOMSON REUTERS

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares

Praxis Precision Medicines Grants RSUs for 11,535 Shares to 66 New Employees Under 2024 Inducement Plan

Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Grants 52,000 Inducement Stock Options at $106.62 Each

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy

Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial

THOMSON REUTERS

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

Dianthus Therapeutics CEO to Join Citi Biopharma Back to School Fireside Chat

Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33

How Machines Decode Human Intent: Wabo Tech's New Frontier in Brain-Computer Interfaces

Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SomnoMed Tightens Insider Trading Rules With New Securities Policy

Scholar Rock to Present at Cantor Global Healthcare Conference Fireside Chat

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/IBRN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":39.3744,"timestamp":1788465600000,"preClose":39.4587,"halted":0,"volume":6342,"delay":0,"changeRate":-0.0021364109816085913,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0843,"latestTime":"09-04 06:29:19 EDT","open":39.87,"high":39.87,"low":39.22,"amount":250291,"amplitude":0.016473,"askPrice":62.6,"askSize":100,"bidPrice":37.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.3744,"sharesOutstanding":150000,"nav":39.408165,"aum":7881633,"dividendRate":0.008114,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.38,"preClose":39.3744,"latestTime":"16:10 EDT","volume":6,"amount":235.9776,"timestamp":1788466204933,"change":0.0056,"changeRate":0.000142,"amplitude":0},"volumeRatio":1.8220997165186916,"impliedVol":0.0707,"impliedVolPercentile":0.247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8220997165186916,"shares":200000,"dividePrice":0.3195,"high":39.87,"amplitude":0.016473,"preClose":39.4587,"low":39.22,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":39.3744,"committee":-0.980198,"eps":0,"divideRate":0.008114,"volume":6342,"delay":0,"ttmEps":0,"open":39.87,"prevYearClose":32.3193,"prevWeekClose":39.2301,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":40.2953,"twentyDayClose":38.5746,"sixtyDayClose":34.7298},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664335196","title":"Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664335196?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:09","pubTimestamp":1788516590,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0N3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","FBT","BK4139","PSCH","ALKS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664236801","title":"Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664236801","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664236801?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:31","pubTimestamp":1788467497,"startTime":"0","endTime":"0","summary":"Dianthus EVP, Head of R&D Simrat Randhawa sells USD 2.45 million in common sharesDianthus Therapeutics EVP, Head of R&D Simrat Randhawa reported option exercises, acquiring 23,124 common shares on Sep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5wp3sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus EVP, Head of R&D Simrat Randhawa Sells USD 2.45 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664480943","title":"Praxis Precision Medicines Grants RSUs for 11,535 Shares to 66 New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480943?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465672,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants RSUs for 11,535 shares to 66 new employees under 2024 inducement planPraxis Precision Medicines granted restricted stock units covering 11,535 common shares to 66 new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLbxsWyw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BFTCPJ56.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","IBRN","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00BQXX3C00.GBP","LU2095319765.USD","LU2210150020.SGD","LU0889565916.HKD","IE00BQXX3F31.USD","BK4585","LU0320765992.SGD","IE00B4R5TH58.HKD","SG9999014005.SGD","IE00B2B36J28.USD","BK4588","BK4112","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0314104364.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","PRAX","BK4139","IE00BN0W2W23.USD","NDAQ","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664180910","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664180910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664180910?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUAX4T6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE0002141913.USD","LU0109394709.USD","LU0320765992.SGD","IBRN","IE00B4R5TH58.HKD","PRAX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580111","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580111?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465660,"startTime":"0","endTime":"0","summary":"Investor Contact:. 857-702-9452. Media Contact:. Dan Ferry. LifeSci Advisors. 617-430-7576","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3356230/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IBRN","ASO","BK4135","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4200","LU0109394709.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4561","IE0009355771.USD","LCLG","PRAX","BK4139","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841493","title":"Dianthus Therapeutics Grants 52,000 Inducement Stock Options at $106.62 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841493?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:01","pubTimestamp":1788382890,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics grants 52,000 inducement stock options at $106.62 eachDianthus Therapeutics granted inducement stock options covering 52,000 shares to four newly hired non-executive employees on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5qpRwy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","NDAQ","SG9999014039.USD","BK4139","DNTH","SG9999014021.USD","SG9999014013.SGD","LU2095319765.USD","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IBRN","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664584117","title":"Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664584117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664584117?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUA4MXXGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819267","title":"Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819267?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:02","pubTimestamp":1788350571,"startTime":"0","endTime":"0","summary":"Scholar Rock begins Phase 2 FORGE trial of apitegromab in facioscapulohumeral muscular dystrophyScholar Rock received FDA Fast Track designation for apitegromab in facioscapulohumeral muscular dystrop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6SFC9d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194998","title":"Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194998","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194998?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:01","pubTimestamp":1788350483,"startTime":"0","endTime":"0","summary":"Scholar Rock says FDA grants fast track status for apitegromab in FSHDFDA granted Fast Track designation for apitegromab in facioscapulohumeral muscular dystrophy, adding to Orphan Drug status for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6lMHWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664139819","title":"Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664139819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664139819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUA23ZKPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864142","title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864142","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864142?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:09","pubTimestamp":1788304180,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson disposes of 9,000 shares for $422,874Craig C. Hopkinson, EVP R&D, Chief Medical Officer, sold 9,000 ordinary shares on Sep. 1 at USD 46.99.He","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLgbNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","ALKS","FBT","PSCH","IBRN","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664209856","title":"Dianthus Therapeutics CEO to Join Citi Biopharma Back to School Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664209856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664209856?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:06","pubTimestamp":1788264366,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics CEO to join Citi Biopharma Back to School fireside chatDianthus Therapeutics will hold investor meetings at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8, 2026.CEO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9bJ7x6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU0072461881.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2417539215.USD","LU0314104364.USD","LU1074936037.SGD","BK4112","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","LU0320765646.SGD","NDAQ","LU1506573853.SGD","LU0648001328.SGD","SG9999014039.USD","LU0980610538.SGD","LU2456880835.USD","LU1244550221.USD","LU2125154778.USD","BK4588","LU1144417596.USD","LU2360032135.SGD","BK4504","LU1201861249.SGD","LU1244550577.SGD","LU1668664300.SGD","LU2125154935.USD","LU0128525689.USD","IE00BSNM7G36.USD","BK4559","TFNS","LU0477156953.USD","LU0310800965.SGD","FTXO","LU1791807156.HKD","IBRN","LU1244550494.USD","LU2236285917.USD","BK4534","IYF","BK4566","DNTH","IE00BN0W2V16.EUR","LU0130517989.USD","LU1267930227.SGD","LU0052756011.USD","IE00B3QW5Z07.USD","LU2462157665.USD","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664652882","title":"Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2664652882","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664652882?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:00","pubTimestamp":1788228028,"startTime":"0","endTime":"0","summary":"Xenon CMO Christopher John Kenney reports disposal of common shares worth $425,469.33Xenon Pharmaceuticals Chief Medical Officer Christopher John Kenney sold 7,068 common shares on Aug. 28, 2026.Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL175Sqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4139","XENE","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104042223","title":"How Machines Decode Human Intent: Wabo Tech's New Frontier in Brain-Computer Interfaces","url":"https://stock-news.laohu8.com/highlight/detail?id=1104042223","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104042223?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:11","pubTimestamp":1788167479,"startTime":"0","endTime":"0","summary":"A drone controlled purely by thought, without a single manual command or voice prompt, once seemed like a scene reserved for sci-fi blockbusters like Avatar. Yet, this is now a reality being...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013901","title":"Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013901?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947270,"startTime":"0","endTime":"0","summary":"Xenon grants 13,450 inducement stock options, 7,850 RSUs to new hires at $61.93 strikeXenon Pharmaceuticals granted inducement equity awards to five new non-officer employees, totaling 13,450 share op","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLbrG4sS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","BK4585","NDAQ","IE00BN0W2T93.GBP","IBRN","BK4588","SG9999014039.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","XENE","SG9999014013.SGD","LU0314104364.USD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","BCDF","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2095319765.USD","SBIO","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013922","title":"Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013922?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nTUA9GT9VC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013769","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013769?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947260,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, Aug.  28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352881/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE","IBRN","LCLG","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662031648","title":"SomnoMed Tightens Insider Trading Rules With New Securities Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662031648","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662031648?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:19","pubTimestamp":1787872792,"startTime":"0","endTime":"0","summary":"The latest update is out from Somnomed Limited ( ($AU:SOM) ). SomnoMed Limited operates in the medical devices sector, focusing on oral appliance t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/somnomed-tightens-insider-trading-rules-with-new-securities-policy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/somnomed-tightens-insider-trading-rules-with-new-securities-policy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEHS","MDTX","HART","HRTS","CURE","XT","IBRN","RSPH","FHLC","BMED","LNGR","MEDI","PINK","AGNG","GDOC","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662702532","title":"Scholar Rock to Present at Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662702532","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662702532?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:02","pubTimestamp":1787832131,"startTime":"0","endTime":"0","summary":"Scholar Rock to present at Cantor Global Healthcare Conference fireside chatScholar Rock will join a fireside chat at the Cantor 2026 Global Healthcare Conference on Sept. 9, 2026 at 8:00 a.m. ET.Management will also participate in a fireside chat at the Citi 2026 BioPharma Back to School Conference on Sept. 10, 2026 at 9:20 a.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire  on August 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL7wl7kq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","LU0980610538.SGD","BK4534","LU1668664300.SGD","LU1244550577.SGD","IE00BSNM7G36.USD","LU2125154935.USD","LU0162691827.USD","LU0098860793.USD","LU1366192091.USD","LU1144417596.USD","LU0477156953.USD","LU0203345920.USD","LU2360032135.SGD","BK4559","BK4139","LU0314106906.USD","SRRK","LU0106831901.USD","BK4585","LU0072461881.USD","LU0128525689.USD","LU1162221912.USD","LU1506573853.SGD","THNR","LU0320765646.SGD","LU0130517989.USD","LU1244550221.USD","TFNS","FTXO","LU2417539215.USD","BK4588","LU0130102774.USD","LU0310800965.SGD","LU2456880835.USD","BK4504","LU2462157665.USD","LU2125154778.USD","LU0648001328.SGD","LU1791807156.HKD","LU1244550494.USD","IYF","LU0170899867.USD","BK4207","LU2236285917.USD","LU0203347892.USD","LU0052756011.USD","IBRN","LU1267930227.SGD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}